FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969285538> ?p ?o ?g. }

• W1969285538 endingPage "68" @default.
• W1969285538 startingPage "68" @default.
• W1969285538 abstract "Background: Novel treatment approaches are paramount for patients with primary refractory MM and PCL, because despite HD chemotherapy, patient median survival is approximately 12 months. The proteasome inhibitor BTZ sensitizes myeloma cells to melphalan both in vitro and in vivo by a mechanism not well understood. In this study we examine the effects of BTZ, followed by BTZ and HD Mel as conditioning regimen for TanPSCT in this poor-risk group. Methods: Patients with primary refractory MM or PCL received 2 cycles of BTZ at 1.3 mg/m2. followed by HD Mel (200 mg/m2) and one dose of BTZ at 0.7 mg/m2, 1.0 mg/m2 or 1.3 mg/m2, as a conditioning regimen prior to TanPSCT. The dose of BTZ was given immediately after the last dose of HD Mel. Bone marrow(BM) samples were collected at baseline, on day 4 and after 2 cycles of BTZ, and at 3 months after TanPSCT, for GEP and Fanconi anemia(FA) pathway genes assessment. Results: To date, 17 patients have been enrolled and treated, and 11 patients are evaluable for response. Median age is 59 years (46–70) with the following myeloma distribution: 55% IgA and 45% IgG. FISH analysis showed the following: del 13q (44%), t (4; 14) (11%), t (11; 14) (11%), trisomy 11 (11%), and polyploid (11%); standard karyotype was normal in 88% of patients and complex karyotype in 12%. Median time to WBC engraftment (days) was 13 and 12 after the first and second transplant, respectively. Median time to plt engraftment (days) was 20 and 17, after the first and second transplant, respectively. There were no dose limiting toxicities. Observed grade 3 toxicities were related to the conditioning regimen and similar to those observed with HDMel alone. One patient developed diffuse alveolar hemorrhage after the first cycle of BTZ, which resolved, but was removed from study. After 2 cycles of BTZ, 45% of patients achieved PR, and 55% had stable disease. Overall response rate at 3 months from the second transplant increased to 90%(CR = 36%, VGPR = 27% andPR = 27%). Only 1 patient developed progressive disease after the first transplant. Evaluations of BM samples by GEP and FA pathway gene expression are underway. Conclusions: Single agent BTZ induced responses in 45% and the combination of HD Mel and BTZ as conditioning regimen for TanPSCT was well tolerated and improved response rates to 90%. These early results suggest that this regimen is very active in this poor-risk group. A Phase II study is underway. Background: Novel treatment approaches are paramount for patients with primary refractory MM and PCL, because despite HD chemotherapy, patient median survival is approximately 12 months. The proteasome inhibitor BTZ sensitizes myeloma cells to melphalan both in vitro and in vivo by a mechanism not well understood. In this study we examine the effects of BTZ, followed by BTZ and HD Mel as conditioning regimen for TanPSCT in this poor-risk group. Methods: Patients with primary refractory MM or PCL received 2 cycles of BTZ at 1.3 mg/m2. followed by HD Mel (200 mg/m2) and one dose of BTZ at 0.7 mg/m2, 1.0 mg/m2 or 1.3 mg/m2, as a conditioning regimen prior to TanPSCT. The dose of BTZ was given immediately after the last dose of HD Mel. Bone marrow(BM) samples were collected at baseline, on day 4 and after 2 cycles of BTZ, and at 3 months after TanPSCT, for GEP and Fanconi anemia(FA) pathway genes assessment. Results: To date, 17 patients have been enrolled and treated, and 11 patients are evaluable for response. Median age is 59 years (46–70) with the following myeloma distribution: 55% IgA and 45% IgG. FISH analysis showed the following: del 13q (44%), t (4; 14) (11%), t (11; 14) (11%), trisomy 11 (11%), and polyploid (11%); standard karyotype was normal in 88% of patients and complex karyotype in 12%. Median time to WBC engraftment (days) was 13 and 12 after the first and second transplant, respectively. Median time to plt engraftment (days) was 20 and 17, after the first and second transplant, respectively. There were no dose limiting toxicities. Observed grade 3 toxicities were related to the conditioning regimen and similar to those observed with HDMel alone. One patient developed diffuse alveolar hemorrhage after the first cycle of BTZ, which resolved, but was removed from study. After 2 cycles of BTZ, 45% of patients achieved PR, and 55% had stable disease. Overall response rate at 3 months from the second transplant increased to 90%(CR = 36%, VGPR = 27% andPR = 27%). Only 1 patient developed progressive disease after the first transplant. Evaluations of BM samples by GEP and FA pathway gene expression are underway. Conclusions: Single agent BTZ induced responses in 45% and the combination of HD Mel and BTZ as conditioning regimen for TanPSCT was well tolerated and improved response rates to 90%. These early results suggest that this regimen is very active in this poor-risk group. A Phase II study is underway." @default.
• W1969285538 created "2016-06-24" @default.
• W1969285538 creator A5004300609 @default.
• W1969285538 creator A5004386819 @default.
• W1969285538 creator A5012866839 @default.
• W1969285538 creator A5017147125 @default.
• W1969285538 creator A5021167699 @default.
• W1969285538 creator A5021617351 @default.
• W1969285538 creator A5024242729 @default.
• W1969285538 creator A5028564361 @default.
• W1969285538 creator A5041163318 @default.
• W1969285538 creator A5051154663 @default.
• W1969285538 creator A5056492087 @default.
• W1969285538 creator A5060783496 @default.
• W1969285538 creator A5068862906 @default.
• W1969285538 creator A5077963733 @default.
• W1969285538 creator A5079158736 @default.
• W1969285538 creator A5083349008 @default.
• W1969285538 creator A5085229837 @default.
• W1969285538 creator A5087799564 @default.
• W1969285538 date "2008-02-01" @default.
• W1969285538 modified "2023-10-18" @default.
• W1969285538 title "184: Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL)" @default.
• W1969285538 doi "https://doi.org/10.1016/j.bbmt.2007.12.193" @default.
• W1969285538 hasPublicationYear "2008" @default.
• W1969285538 type Work @default.
• W1969285538 sameAs 1969285538 @default.
• W1969285538 citedByCount "0" @default.
• W1969285538 crossrefType "journal-article" @default.
• W1969285538 hasAuthorship W1969285538A5004300609 @default.
• W1969285538 hasAuthorship W1969285538A5004386819 @default.
• W1969285538 hasAuthorship W1969285538A5012866839 @default.
• W1969285538 hasAuthorship W1969285538A5017147125 @default.
• W1969285538 hasAuthorship W1969285538A5021167699 @default.
• W1969285538 hasAuthorship W1969285538A5021617351 @default.
• W1969285538 hasAuthorship W1969285538A5024242729 @default.
• W1969285538 hasAuthorship W1969285538A5028564361 @default.
• W1969285538 hasAuthorship W1969285538A5041163318 @default.
• W1969285538 hasAuthorship W1969285538A5051154663 @default.
• W1969285538 hasAuthorship W1969285538A5056492087 @default.
• W1969285538 hasAuthorship W1969285538A5060783496 @default.
• W1969285538 hasAuthorship W1969285538A5068862906 @default.
• W1969285538 hasAuthorship W1969285538A5077963733 @default.
• W1969285538 hasAuthorship W1969285538A5079158736 @default.
• W1969285538 hasAuthorship W1969285538A5083349008 @default.
• W1969285538 hasAuthorship W1969285538A5085229837 @default.
• W1969285538 hasAuthorship W1969285538A5087799564 @default.
• W1969285538 hasBestOaLocation W19692855381 @default.
• W1969285538 hasConcept C126322002 @default.
• W1969285538 hasConcept C126894567 @default.
• W1969285538 hasConcept C141071460 @default.
• W1969285538 hasConcept C2776364478 @default.
• W1969285538 hasConcept C2776694085 @default.
• W1969285538 hasConcept C2777478702 @default.
• W1969285538 hasConcept C2778684742 @default.
• W1969285538 hasConcept C2781413609 @default.
• W1969285538 hasConcept C31760486 @default.
• W1969285538 hasConcept C71924100 @default.
• W1969285538 hasConcept C90924648 @default.
• W1969285538 hasConceptScore W1969285538C126322002 @default.
• W1969285538 hasConceptScore W1969285538C126894567 @default.
• W1969285538 hasConceptScore W1969285538C141071460 @default.
• W1969285538 hasConceptScore W1969285538C2776364478 @default.
• W1969285538 hasConceptScore W1969285538C2776694085 @default.
• W1969285538 hasConceptScore W1969285538C2777478702 @default.
• W1969285538 hasConceptScore W1969285538C2778684742 @default.
• W1969285538 hasConceptScore W1969285538C2781413609 @default.
• W1969285538 hasConceptScore W1969285538C31760486 @default.
• W1969285538 hasConceptScore W1969285538C71924100 @default.
• W1969285538 hasConceptScore W1969285538C90924648 @default.
• W1969285538 hasIssue "2" @default.
• W1969285538 hasLocation W19692855381 @default.
• W1969285538 hasOpenAccess W1969285538 @default.
• W1969285538 hasPrimaryLocation W19692855381 @default.
• W1969285538 hasRelatedWork W1989604393 @default.
• W1969285538 hasRelatedWork W2022680061 @default.
• W1969285538 hasRelatedWork W2024123206 @default.
• W1969285538 hasRelatedWork W2096207943 @default.
• W1969285538 hasRelatedWork W2112489854 @default.
• W1969285538 hasRelatedWork W2237938743 @default.
• W1969285538 hasRelatedWork W2567755155 @default.
• W1969285538 hasRelatedWork W2588907662 @default.
• W1969285538 hasRelatedWork W2626247867 @default.
• W1969285538 hasRelatedWork W3134875278 @default.
• W1969285538 hasVolume "14" @default.
• W1969285538 isParatext "false" @default.
• W1969285538 isRetracted "false" @default.
• W1969285538 magId "1969285538" @default.
• W1969285538 workType "article" @default.